

Appendix Table F73. Constipation after pharmacological treatments for UI when compared to each other

| Reference | Active drug | Dose | Control drug | Dose | Active n/N | Control n/N | Relative risk (95% CI) | Absolute risk difference (95% CI) |
|--------------------------------|----------------|------------------|----------------|------------------|------------|-------------|------------------------|-----------------------------------|
| Zinner, 2005 ⁴¹² | Darifenacin ER | 15mg/day | Oxybutynin | 5 mg 3 times/day | 2/19 | 2/19 | 1.0(0.2; 6.4) | 0.00 (-0.20; 0.20) |
| Halaska, 2003 ³⁰² | Trospium | 40mg/day | Oxybutynin | 10mg/day | 18/267 | 4/90 | 1.5(0.5; 4.4) | 0.02 (-0.03; 0.08) |
| Halaska, 2003 ³⁰² | Trospium | 20mg twice daily | Oxybutynin | 5mg twice daily | 18/267 | 4/90 | 1.5(0.5; 4.4) | 0.02 (-0.03; 0.08) |
| Chapple, 2004 ²⁶⁵ | Solifenacin | 2.5mg once daily | Tolterodine | 2mg twice daily | 1/41 | 1/37 | 0.9(0.1; 13.9) | 0.00 (-0.07; 0.07) |
| Chapple, 2004 ²⁶⁵ | Solifenacin | 5mg once daily | Tolterodine | 2mg twice daily | 5/37 | 1/37 | 5.0(0.6; 40.8) | 0.11 (-0.01; 0.23) |
| Chapple, 2004 ²⁶⁵ | Solifenacin | 10mg once daily | Tolterodine | 2mg twice daily | 2/35 | 1/37 | 2.1(0.2; 22.3) | 0.03 (-0.06; 0.12) |
| Chapple, 2004 ²⁶⁵ | Solifenacin | 20mg once daily | Tolterodine | 2mg twice daily | 6/37 | 1/37 | 6.0(0.8; 47.4) | 0.14 (0.01; 0.26) |
| Chapple, 2004 ⁵⁴ | Solifenacin | 5mg daily | Tolterodine | 2mg twice daily | 20/279 | 7/266 | 2.7(1.2; 6.3) | 0.05 (0.01; 0.08) |
| Chapple, 2004 ⁵⁴ | Solifenacin | 10mg daily | Tolterodine | 2mg twice daily | 21/269 | 7/266 | 3.0(1.3; 6.9) | 0.05 (0.01; 0.09) |
| Chapple, 2005 ²⁵⁸ | Darifenacin ER | 15mg daily | Oxybutynin IR | 5mg t.i.d. | 8/12 | 6/12 | 1.3(0.7; 2.7) | 0.17 (-0.22; 0.56) |
| Chapple, 2005 ²⁵⁸ | Darifenacin ER | 30mg daily | Oxybutynin IR | 5mg t.i.d. | 10/13 | 2/12 | 4.6(1.3; 16.9) | 0.60 (0.29; 0.91) |
| Chapple, 2005 ²⁵⁸ | Darifenacin IR | 2.5 t.i.d. | Oxybutynin IR | 2.5 t.i.d. | 1/8 | 1/8 | 1.0(0.1; 13.4) | 0.00 (-0.32; 0.32) |
| Chapple, 2005 ⁶¹ | Solifenacin | 5-10mg od | Tolterodine | 4mg once daily | 3/578 | 1/599 | 3.1(0.3; 29.8) | 0.00 (0.00; 0.01) |
| Zinner, 2005 ⁴¹² | Darifenacin ER | 30mg/day | Oxybutynin | 5 mg 3 times/day | 4/19 | 2/19 | 2.0(0.4; 9.6) | 0.11 (-0.12; 0.33) |
| Armstrong, 2007 ²³² | Oxybutynin | 10mg qd | Tolterodine ER | 4mg qd | 38/576 | 31/399 | 0.8(0.5; 1.3) | -0.01 (-0.04; 0.02) |
| Armstrong, 2007 ²³² | Oxybutynin | 10mg qd | Tolterodine ER | 2mg qd | 38/576 | 12/193 | 1.1(0.6; 2.0) | 0.00 (-0.04; 0.04) |
| Chapple, 2007 ²⁶³ | Solifenacin | 5mg daily | Tolterodine | 4mg daily | 12/578 | 7/599 | 1.8(0.7; 4.5) | 0.01 (-0.01; 0.02) |
| Chapple, 2007 ²⁵⁹ | Tolterodine | 4mg daily | Fesoterodine | 8mg daily | 8/290 | 13/288 | 0.6(0.3; 1.5) | -0.02 (-0.05; 0.01) |

Appendix Table F73. Constipation after pharmacological treatments for UI when compared to each other (continued)

| Reference | Active drug | Dose | Control drug | Dose | Active n/N | Control n/N | Relative risk (95% CI) | Absolute risk difference (95% CI) |
|--------------------------------|----------------|---------------------------|----------------|---------------------------|------------|-------------|------------------------|-----------------------------------|
| Chapple, 2007 ²⁵⁹ | Tolterodine | 4mg daily | Fesoterodine | 4mg daily | 8/290 | 9/272 | 0.8(0.3; 2.1) | -0.01 (-0.03; 0.02) |
| Yamaguchi, 2007 ⁴¹⁰ | Solifenacin | 5mg daily | Propiverine | 20mg daily | 42/400 | 45/402 | 0.9(0.6; 1.4) | -0.01 (-0.05; 0.04) |
| Yamaguchi, 2007 ⁴¹⁰ | Solifenacin | 10mg daily | Propiverine | 20mg daily | 72/385 | 45/402 | 1.7(1.2; 2.4) | 0.08 (0.03; 0.12) |
| Chapple, 2008 ²⁶⁰ | Tolterodine | 4mg daily | Fesoterodine | 8mg daily | 8/290 | 13/287 | 0.6(0.3; 1.4) | -0.02 (-0.05; 0.01) |
| Choo, 2008 ²⁶⁸ | Solifenacin | 5mg once daily | Tolterodine IR | 2mg twice daily | 8/120 | 3/118 | 2.6(0.7; 9.6) | 0.04 (-0.01; 0.09) |
| Choo, 2008 ²⁶⁸ | Solifenacin | 10mg once daily | Tolterodine IR | 2mg twice daily | 17/119 | 3/118 | 5.6(1.7; 18.7) | 0.12 (0.05; 0.19) |
| Sand, 2009 ³⁷² | Tolterodine | 4mg daily | Fesoterodine | 8mg daily | 6/227 | 24/452 | 0.5(0.2; 1.2) | -0.03 (-0.06; 0.00) |
| Sand, 2009 ³⁷² | Tolterodine | 4mg daily | Fesoterodine | 4mg daily | 6/227 | 20/434 | 0.6(0.2; 1.4) | -0.02 (-0.05; 0.01) |
| Zellner, 2009 ⁴¹¹ | Trospium | 15mg to 30mg thrice daily | Oxybutynin | 2.5mg to 5mg thrice daily | 10/828 | 1/830 | 0.1(0.0; 0.8) | 0.01 (0.003; 0.02) |
| Herschorn, 2010 ⁴⁷⁵ | Tolterodine ER | 4mg once daily | Fesoterodine | 4-8mg once daily | 28/684 | 37/679 | 0.8(0.5; 1.2) | -0.01 (-0.04; 0.01) |
| Kaplan, 2010 ³²² | Fesoterodine | 4 to 8mg once daily | Tolterodine ER | 4 mg once daily | 270/963 | 29/974 | 9.4(6.5; 13.7) | 0.25 (0.22; 0.28) |
| Milani, 1993 ³⁴⁸ | Flavoxate | 1200 | Oxybutynin | 5mg t.i.d. | 1/50 | 2/50 | 0.5(0.0; 5.3) | -0.02 (-0.09; 0.05) |
| NCT00444925, 58 | Fesoterodine | 4 to 8mg once daily | Tolterodine ER | 4 to 8mg once daily | 37/685 | 28/690 | 1.3(0.8; 2.1) | 0.01 (-0.01; 0.04) |